ARTV insider trading
NasdaqGM HealthcareArtiva Biotherapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Company website: www.artivabio.com
ARTV insider activity at a glance
FilingIQ tracks 122 insider transactions for ARTV in filings since Jul 22, 2024. The most recent transaction is dated Sep 15, 2026.
Across the full history, 30 open-market purchases
and 16 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ARTV insider trades is 53.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ARTV Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ARTV?
- FilingIQ tracks 122 Form 4 insider transactions for ARTV (Artiva Biotherapeutics, Inc.), covering filings from Jul 22, 2024 onwards. 26 of those are dated within the last 90 days.
- Are ARTV insiders net buyers or net sellers?
- Across the full Form 4 history for ARTV, 30 transactions (25%) were open-market purchases and 16 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ARTV insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ARTV in?
- Artiva Biotherapeutics, Inc. (ARTV) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $415.43M.
Methodology & sources
Every ARTV insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.